AcuCort AB (publ) carries out a rights issue of shares of around MSEK 41.2. The funds contributed to the company through the rights issue shall primarily be used for the financing of the imminent commercialisation of AcuCort’s innovative drug candidate ISICORT®.
AcuCort develops and commercializes ISICORT® – a new fast-dissolving film that is placed on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting. The bioequivalence study that forms the basis of the application for market approval in Europe is carried out with positive results, which strengthens the assessment that the time until commercialisation of ISICORT® may be relatively short. The AcuCort share is traded at Spotlight Stock Market in Sweden.
HWF Advokater acts as legal advisor to AcuCort in connection with the rights issue.